Better Biotech Stock: Biogen vs. Annovis Bio
When you're evaluating two companies that will compete for the same target market, it's a bit like betting on a boxing match. By judging what each business is capable of before the match starts, keen investors can calculate the odds and pick a profitable bet. Of course, when we're looking at a pair of biotech stocks, the competition will end up being significantly slower than boxing.
In this showdown, the arena is the market for Alzheimer's disease therapeutics, and there are two noteworthy contenders. In one corner, there's the reigning champion, Biogen (NASDAQ: BIIB), the maker of Aduhelm, an Alzheimer's drug which regulators recently approved for sale, a move that was met with great controversy including a Congressional investigation. And in the other corner, there's the scrappy Annovis Bio (NYSEMKT: ANVS), a significantly smaller company that's working on an Alzheimer's therapy which could be significantly more effective than Aduhelm. There's an argument in favor of both stocks, but the most important thing for investors is that the bout has already begun.
Image source: Getty Images.
Source Fool.com
